In this expert discussion, Drs. Michael Levine and Aliya Khan review emerging evidence in autosomal dominant hypocalcemia type 1 (ADH1), including findings from the CALIBRATE trial presented at ENDO 2026. They discuss how CaSR-targeted therapy with encaleret may address the underlying disease mechanism and highlight key efficacy and safety findings, including reductions in hypercalciuria and the potential implications for long-term renal health. The faculty also examine the role of genetic testing in establishing an accurate diagnosis, guiding family screening, and preparing clinicians for emerging precision medicine approaches in ADH1.
Credit & MOC Details
Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.
Credit types
MOC types
FDA REMS
Qualifies for MIPS
Target Specialties
Address:
- 1301 Virginia Drive
Pricing
CME included with membership
| Free Registration | Free |
| Tufts-Affiliated HCP - Early Bird (by 10/5/26) | $75 |
| Tufts-Affiliated HCP - Standard | $175 |
| Trainees & Allied Health - Early Bird (by 10/5/26) | $75 |
| Trainees & Allied Health - Standard | $175 |
| Physicians - Early Bird (by 10/5/26) | $150 |
+3 more tiers
Collected from the provider’s public pages · source
Specialties served/covered
- Advanced Heart Failure & Transplant Cardiology
- Allergy & Clinical Immunology
- Cardiovascular Disease
- Communication & Shared Decision-Making
- Dermatology
- Diagnostic Radiology
- Endocrinology, Diabetes & Metabolism
- Family Medicine
- Gastroenterology
- General & Adult Psychiatry
- General Pediatrics
- Gynecologic Oncology
- Head & Neck Surgery
- Hematology
- Maternal-Fetal Medicine
- Medical Genetics & Genomics
- Medical Oncology
- Mood & Anxiety Disorders
- Nephrology
- Neurology
- Neuromuscular Medicine
- Neuroradiology
- Obstetrics & Gynecology
- Ophthalmology
- Pediatric Neurology
- Psychopharmacology
- Psychotic Disorders
- Pulmonary Disease
- Radiation Oncology
- Rheumatology
- Sleep Medicine
- Surgical Oncology
- Transplant Hepatology
- Urological Oncology
- Vascular Neurology
- Cardio-Vascular
- Cross-Specialty
- ENT & Head Neck
- GI & Liver
- Medical Subspecialties
- Neurology
- Ob/Gyn
- Oncology & Hematology
- Pediatrics
- Primary care
- Psychiatry
- Radiology
- Surgery
- Urology
- No reviews yet. Be the first to share yours.
Pricing
Free
Reported to ACCME by the provider
- Enduring / On-demand
- Credit · Up to 0.25 credits
- Commercial Support
-
ReleasedJul 31, 2026
-
Last day to claim creditAug 1, 2027 10 months left
-
The HypoPARAthyroidism Association, Inc +1 Uncovering a Hidden Driver of Hypoparathyroidism: Improving ADH1 Detection and Cracking the Case With CaSR-Targeted Therapies (FMX)
-
France Foundation, The Hypoparathyroidism The Critical Role of Genetics in Your Differential Diagnosis
-
Baylor College of Medicine Precision Medicine Initiative: Mild Hypercalcemia and Screening for Primary Hyperparathyroidism – Part 1: Introduction – Overall Project Description
-
Global Learning Collaborative Advances in Treatment of Hypoparathyroidism: Importance of Genetic Testing for Autosomal Dominant Hypocalcemia Type 1
-
Global Learning Collaborative From Evidence to Action: Advancing Care in Severe Hypertriglyceridemia and Familial Chylomicronemia Syndrome
-
Global Learning Collaborative Targeting CKD-aP at the Source: Key Mechanisms and Treatments
